| X-linked agammaglobulinemia
Flebogamma DIF 5% vs Cuvitru
Side-by-side clinical, coverage, and cost comparison for x-linked agammaglobulinemia.Deep comparison between: Flebogamma vs Cuvitru with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCuvitru has a higher rate of injection site reactions vs Flebogamma based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cuvitru but not Flebogamma, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Flebogamma
Cuvitru
At A Glance
IV infusion
Every 3-4 weeks
Immune globulin (IGIV)
SC injection
Daily to every 2 weeks
Immune globulin replacement (IgG)
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Severe Combined Immunodeficiency
- Wiskott-Aldrich Syndrome
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome 300-600 mg per kg body weight IV every 3-4 weeks; initial infusion rate 0.01 mL/kg/min (0.5 mg/kg/min), increased to maximum 0.10 mL/kg/min (5 mg/kg/min) if tolerated.
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC infusion administered daily to every 2 weeks; patients switching from IGIV begin 1 week after last IGIV dose with initial weekly dose (g) = previous IGIV dose (g) x 1.30 divided by weeks between IGIV doses; patients switching from IGSC use the same weekly dose; monitor serum IgG trough levels to guide adjustments.
Contraindications
- History of anaphylactic or severe systemic hypersensitivity reactions to human immune globulin
- IgA-deficient patients with antibodies to IgA and a history of hypersensitivity
- Previous anaphylactic or severe systemic hypersensitivity reaction to subcutaneous administration of human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
Adverse Reactions
Most common, adults (>=5%) Headache, pyrexia, pain, injection site reactions, diarrhea, rigors, urticaria, infusion site inflammation
Most common, pediatrics (>=5%) Headache, pyrexia, hypotension, tachycardia, diastolic hypotension, nausea, abdominal pain, diarrhea, pain, vomiting
Postmarketing Hypersensitivity/anaphylaxis, acute renal dysfunction/failure, ARDS, TRALI, cardiac arrest, thromboembolism, coma, seizures, aseptic meningitis syndrome, Stevens-Johnson Syndrome, pancytopenia, hemolysis
Most common (>=5%) Local adverse reactions, headache, nausea, fatigue, diarrhea, vomiting
Postmarketing Aseptic meningitis, anaphylactic reaction, tachycardia, tremor, paresthesia, dyspnea, laryngospasm, injection site reaction (induration, warmth), chest discomfort
Pharmacology
Flebogamma 5% DIF is an intravenous immune globulin (IGIV) that provides replacement therapy for primary immunodeficiency by supplying a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.
CUVITRU is a human IgG replacement product that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, restoring abnormally low IgG levels to the normal range in patients with primary humoral immunodeficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Flebogamma
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Cuvitru
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Flebogamma
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Cuvitru
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Flebogamma
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Cuvitru
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Flebogamma.
Cost estimate not availableAccessia Health: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FlebogammaView full Flebogamma profile
CuvitruView full Cuvitru profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.